Trilobatin attenuates blood-brain barrier dysfunction induced by cerebral ischemia reperfusion by targeting MMP9: Involvement of APOE4/CypA/NF-κB signaling

Linying Feng¹, Yeli Li¹, Mu Lin¹, Dianyou Xie¹, Yunmei Luo¹, Nana Chen², Zhi-Xu He², Qihai Gong², Zhu Yizhun¹, and Jianmei Gao²

¹Macau University of Science and Technology
²Zunyi Medical University

September 24, 2022

Abstract

Background and Purpose: Blood-brain barrier (BBB) breakdown is one of the most crucial pathological changes of cerebral ischemia-reperfusion (I/R) injury. Trilobatin (TLB), a naturally occurring food additive, exerts neuroprotective effect against cerebral I/R injury as demonstrated in our previous study. This study was designed to investigate the effect of TLB on disruption of BBB after cerebral I/R injury. Experimental Approach: Rats with focal cerebral ischemia caused by transient middle cerebral artery occlusion (MCAO) and brain microvascular endothelial cells along with human astrocytes to mimic blood brain barrier (BBB) injury caused by oxygen and glucose deprivation (OGD) followed by reoxygenation (OGD/R). Key results: The results showed that TLB effectively maintained the integrity of BBB and inhibited neuronal loss following cerebral I/R challenge. Furthermore, TLB dramatically increased tight junction proteins including ZO-1, occludin and claudin 5, as well as decreased the levels of apolipoprotein E (APOE) 4, cyclophilin A (CypA), and phosphorylated nuclear factor kappa B (NF-κB), thereby reduced proinflammatory cytokines. In addition, TLB also decreased Bax/Bcl-2 ratio and cleaved-caspase 3 level along with reduced the number of apoptotic neurons. Intriguingly, molecular docking and transcriptomics predicted MMP9 was a prominent gene evoked by TLB treatment. Furthermore, the protective effect of TLB on OGD/R-induced the loss of BBB integrity in human brain microvascular endothelial cell and astrocyte co-cultures in vitro was markedly reinforced by knockdown of MMP9. Conclusions and implications: Our findings reveal a novel property of TLB: saving BBB disruption following cerebral I/R via targeting MMP9 and inhibiting APOE4/CypA/NF-κB axis.

Gao Jianmei (Orcid ID: 0000-0003-3683-7956)

Τριλοβατιν αττενυατεσβλοοδ-βραιν βαρριερ δψσφυνςτιον ινδυςεδ βψ ςερεβραλ ισςηεμια ρεπερφυσιον βψ ταργετινγ ΜΜΠ9: Ινολεμεντ αφ ΑΠΟΕ4/ΦψπΑ/ΝΦ-κΒ σιγναλινγ

Linying Feng¹,², Yeli Li¹,², Mu Lin¹,², Dianyou Xie¹,², Yunmei Luo¹,², Nana Chen², Zhixu He³, Qihai Gong¹,², Yizhun Zhu¹, Jianmei Gao¹,²*

¹Department of Pharmacy, Macau University of Science and Technology, Macau, China
²Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China
³The Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi medical University

Corresponding author: Prof. Jianmei Gao, Ph.D.
Acknowledgements

This work was supported by Natural Science Foundation of China (No.82160756), Science and Technology Support Plan of Guizhou Province (No. [2020]1Y010), The hundred level of high-level innovative talents in Guizhou Province (No. QKHRCPPT 20165684), Collaborative Innovation Center of Chinese Ministry of Education (No. 2020-39), Science and technology planning project of Zunyi (No. [HZ2021]187), The Natural Science Foundation of Guizhou, China (No.2019-1329).

Author contribution

LYF, YLL, ML, and NNC performed the experiments. DYX and YML helped with bioinformatics analysis and molecular docking analysis. All authors were involved in analysis of data. LYF wrote the manuscript. JMG, QHG, YZZ, and HZX design the experiments and revised the manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Declaration of transparency and scientific rigour

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJP guidelines for Design & Analysis, Immunoblotting and Immunochemistry and Animal Experimentation and as recommended by funding agencies, publishers and other organizations engaged with supporting research.

Data availability statement

The authors declare that data supporting the findings of this study are available within the article and it’s Supplementary information (Supplementary SFig.1, 2). Uncropped Western blots are shown in Supplementary material. All relevant datasets used and/or analyzed in this study are available from the corresponding author upon reasonable request.

Hosted file

Supplementary Materials

**Supplementary Fig. S1** Effects of TLB on BBB integrity breakdown induced by OGD 4 h/R 24 h in human BMEC/astrocytes co-cultures. Human BMEC/astrocytes were treated with TLB or without at different concentrations (12.5, 25, 50 μM) for 24 h. a. TEER value (n = 6). b. Cell viability (n = 6). c. LDH leakage (n = 6). Data are presented as mean ± SD. **P<0.01 versus Control group; #P< 0.05, ##P< 0.01 versus OGD/R group.

**Supplementary Fig. S2** Knockdown of MMP9 by small interfering RNA (siRNA).

a. The presentative western blot shown for MMP9 siRNA. b. Quantitation of MMP9. Data are presented as mean ± SD, **P<0.01 versus Control group; n = 6 per group.
The BBB was impaired in the peri-infarct tissue after I/R injury. Furthermore, astrocytes regulate MMP9 expression in pericytes, and this regulation is mediated by astrocyte-derived apolipoprotein E (ApoE). Specifically, TLB, which in turn inhibits the proinflammatory cyclophilin A (CypA)/NF-κB/MMP9 pathway and reduces the degradation of TJs and BM proteins in the BBB in rats.